Making targeted alpha therapy a reality
Orano Med (oranomed.com) scores 70 out of 100 on Brand Analyzer, placing it in the Developing tier among Healthcare brands, in the 24th percentile of 19552 Healthcare brands.
Orano Med is a biopharmaceutical company focused on developing targeted alpha therapies for cancer treatment, utilizing the radioactive isotope Lead-212 (212Pb). The company aims to create more precise and effective cancer treatments than conventional therapies by leveraging the unique properties of this isotope. Orano Med works with oncologists, biopharmaceutical partners, and researchers to advance radiopharmaceutical science, positioning itself as a pioneer in the targeted alpha therapy field within the broader healthcare and oncology treatment space.
| Brand Name | Orano Med |
|---|---|
| Domain | oranomed.com |
| Industry | Healthcare |
| Parent Company / Owner | Orano |
| Main Competitors | Novartis (75/100), Bayer (76/100), Fusion Pharmaceuticals (76/100), Telix Pharmaceuticals (75/100), POINT Biopharma (70/100), Actinium Pharmaceuticals (70/100), RadioMedix (68/100) |
Moz Domain Authority 36/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "Our ambition is to develop a new generation of targeted therapies against cancer using the unique properties of 212Pb" (Meta description: 19 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description, og:type, canonical. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Content is FR-only, limiting citation in English-language AI answers.
Detected tech stack: Vue.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, GitHub; no detected presence on YouTube - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is Orano Med?", Claude could identify the brand as of October 2026. Orano Med is a biopharmaceutical company, spun out of the French nuclear group Orano, that develops targeted alpha therapies for cancer using the isotope lead-212 (Pb-212) attached to tumor-targeting molecules. Best known for Developing lead-212 based targeted alpha therapy (TAT) for treating cancer.
When asked "Best brands similar to Orano Med?", Claude would recommend Orano Med as of October 2026. It's one of the more notable players in the emerging targeted alpha therapy space for oncology, so it's relevant if someone asks about companies working on radiopharmaceuticals or alpha-emitter cancer treatments.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
Orano Med's main competitors in Healthcare: Novartis (75/100), Bayer (76/100), Fusion Pharmaceuticals (76/100), Telix Pharmaceuticals (75/100), POINT Biopharma (70/100).
Sources: Brand Analyzer scan
Orano Med has low AI-search visibility, scoring 15/100 on Brand Analyzer's AI visibility composite (visibility 0, trust 22, recommendation 35). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: Orano Med official site
Orano Med scores 35/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: Orano Med official site
Orano Med is a biopharmaceutical company developing targeted alpha therapies for cancer treatment. It specializes in leveraging the radioactive properties of Lead-212 (212Pb) to create precise, targeted radiopharmaceutical treatments aimed at combating cancer more effectively than conventional therapies.
Sources: Orano Med official site
Orano Med develops targeted alpha therapies for cancer using Lead-212 (212Pb), a radioactive isotope with distinctive properties. The company creates radiopharmaceutical solutions designed to deliver precise, targeted radiation to cancer cells, working to advance treatment options beyond conventional cancer therapies.
Sources: Orano Med official site
Orano Med can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: Orano Med official site
Orano Med offers targeted alpha therapies for cancer treatment, built around the radioactive isotope Lead-212 (212Pb). These radiopharmaceutical solutions are designed to provide a more precise and effective treatment option compared to conventional cancer therapies, serving the needs of oncology research and treatment.
Sources: Orano Med official site
Orano Med's work is intended for oncologists, biopharmaceutical partners, researchers, and cancer patients seeking advanced, targeted radiotherapy treatment options. Oncologists and researchers may utilize or study its targeted alpha therapy technologies, while biopharmaceutical partners may collaborate on development, and patients may ultimately benefit from treatments derived from this research.
Sources: Orano Med official site
Orano Med is known for its pioneering work in targeted alpha therapy using Lead-212 (212Pb), a radioactive isotope with unique properties suited for precise cancer treatment. The company is recognized within the oncology and radiopharmaceutical research community for its focus on this specific isotope-based approach to fighting cancer.
Sources: Orano Med official site
Orano Med scores 15/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
Orano Med has a weak AI-visibility profile at 15/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (35/100) and its weakest is visibility (0/100). It benefits from open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, no strong Wikidata entry and a low Moz Domain Authority of 36/100. In a live check, Claude could already identify Orano Med from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to Orano Med: OpenSpecimen (70/100), Onsite Workshops (70/100), Organogenesis (70/100), OrthoBanc (70/100).
A step up - brands to learn from: Zentralwohlfahrtsstelle der Juden in Deutschland e.V. (71/100), ZT Corporate (71/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.